Gaps in Evidence for the Use of Medically Authorized Cannabis: Ontario and Alberta, Canada

Cerina Lee
University of Alberta School of Public Health

Jessica M Round
University of Alberta School of Public Health

Scott Klarenbach
University of Alberta Faculty of Medicine & Dentistry

John G Hanlon
University of Toronto Department of Anaesthesiology and Pain Medicine

Elaine Hyshka
University of Alberta School of Public Health

Jason R.B. Dyck
University of Alberta Faculty of Medicine & Dentistry

Dean T Eurich (✉ deurich@ualberta.ca )
University of Alberta  https://orcid.org/0000-0003-2197-0463

Research Article

**Keywords:** medical cannabis, epidemiology, cohort study, chronic pain, anxiety, depression, cancer, spasticity, nausea.

**DOI:** https://doi.org/10.21203/rs.3.rs-405117/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

With legal access to medical cannabis in Canada since 2001, there is a need to fully characterize its use at both the individual and population-level. We draw on data from Canada’s largest cohort study of medical cannabis to identify the primary reasons for medical cannabis authorization in Canada from 2014–2019 in two major Provinces: Alberta (AB) and Ontario (ON); and review the extent that evidence supports each indication.

Methods

Self-reported outcomes were collected from adult patients in ON (n = 61835) and AB (n = 3410) who were authorized medical cannabis. At baseline, sociodemographic, primary medical information, and validated clinical questionnaires were completed by patients as part of an individual assessment. Patients’ reasons for seeking medical cannabis were compared to published reviews and guidelines to assess the level of evidence supporting medical cannabis use for each condition.

Results

Medical cannabis use in both AB and ON were similar in both demographic and reason for authorization. The most common reasons for medical cannabis authorization were: 1) pain (AB = 77%, ON = 76%) primarily due to chronic musculoskeletal, arthritic, and neuropathic pain, 2) mental health concerns (AB = 32.9%, ON = 38.7%) due to anxiety and depression, and 3) sleep problems (AB = 28%, ON = 25%). More than 50 other conditions were identified as reasons for obtaining authorization.

Conclusion

In both AB and ON, the majority of reasons for medical cannabis authorization are not substantiated by evidence to fully support its efficacy for long-term use. Ongoing epidemiological studies on medical cannabis on these treatments are warranted to fully outline its treatment benefits or risks.

Introduction

The legal access of medical cannabis has been available to patients as a potential therapeutic avenue of treatment for nearly a decade in Canada(1). Although legally available, there is an absence of randomized controlled trials and high-quality longitudinal cohort studies that support cannabis as a proven medical therapy(2). This evidence gap persists in the medical cannabis research field that hinders clinicians and physicians ability to provide evidence-based healthcare to patients seeking medical cannabis for a wide spectrum of therapeutic needs(3). With the recent legalization of non-medical
cannabis (October 2018) in Canada, there has been a growing public interest in the therapeutic use of cannabis. Thus, medical evidence is needed to support its use. Consequently, this will enable physicians to make clinically informed healthcare decisions surrounding medical cannabis authorization.

To date, systematic reviews and clinical studies have reported a wide spectrum of underlying reasons for medical cannabis prescription - with mixed outcomes on both the types of reasons for use and evidence on efficacy for its therapeutic effects. The majority of clinical studies most frequently report the following reasons for its authorization: i) chronic pain (back pain, neuropathic pain, arthritic pain, pain from non-cancer and cancer, etc); ii) mental health conditions (anxiety, depression); iii) autoimmune disorders; iv) sleep problems; v) neurological; vi) gastrointestinal; and vii) other health conditions such as chemo-induced nausea/vomiting. There also has been an increasing frequency of medical cannabis use as an alternative to opioids for patients. With the exception of neuropathic chronic pain, chemo-therapy induced nausea/vomiting and certain spasticity symptoms, the majority of previous studies concur that there is very weak evidence regarding its clinical effectiveness. Furthermore, the studies to date are predominantly limited to small cohort sample sizes, very few are conducted within Canada, and the majority do not differentiate between medical and nonmedical cannabis usage. Duration of trials and limitations in blinding are also significant limitations.

Currently, two guidelines guide medical cannabis authorizers and outline the best-available evidence. In both guidelines, clinicians report caution with utilizing cannabis as a first- or second-line treatment for any type of health condition. Despite substantive evidence for the therapeutic effects of medical cannabis on chronic pain (cancer, arthritic, neurologic, musculoskeletal pain), there is insufficient or limited evidence for medical cannabis use on the majority of other health conditions. Yet, medical cannabis is being used as a treatment. The objective of this paper is to characterize the primary reasons for medically authorized cannabis use in a large cohort of patients in Ontario (ON) and Alberta (AB), Canada; and to descriptively compare these conditions with current recommendations for use of medical cannabis in Canada.

**Methods**

**Study Design & Population**

A cohort study was conducted of all adult patients authorized medical cannabis [inhaled (smoked or vaporized) or orally consumed cannabis] attending a chain of specialized clinics in AB and ON, Canada between April 2014 and January 2019. Our study includes individuals at least 18 years of age, of any sex and ethnicity, who received medical cannabis authorization for any indication (acute and chronic). Patients may choose to seek assessment for medical cannabis through the clinic via a self-referral or by a physician referral.
Data Source

Informed written consent was provided by the patient at intake, which allowed data to be collected and used for clinical and research purposes. As part of the intake process, each patient seeking medical cannabis met with a counselor who performed an initial assessment and collected relevant data. All patients must provide sociodemographic information and disclose their primary medical complaints that constitute their rationale for requesting medical cannabis authorization. Many patients completed self-reported assessments to assist physicians in determining whether the patient was a suitable candidate for medical cannabis. These assessments included: the Generalized Anxiety Disorder 7-item (GAD-7) scale; Patient Health Questionnaire (PHQ-9); and the CAGE Questionnaire Adapted to Include Drugs (CAGE-AID). Following their initial intake interview, the patient would then be referred to a physician who makes their assessment based on the self-reported information, the patient’s health record, and any additional relevant health information.

Patient and Public Involvement

Patients and the public were not involved in designing, conducting, or reporting this research project as it was not directly applicable to this project.

Ethics Approval

The study was approved by the University of Alberta Health Research Ethics Board (PRO 00068887) and the Veritas Research Ethics Board in Ontario (16111-13:21:103-01-2017).

Descriptive Analyses

For each province, sociodemographic characteristics including age at authorization, sex, neighbourhood average income quintile, GAD-7, PHQ-9, and CAGE-Aid score, and reason for cannabis use were analyzed descriptively using counts and percentages. Neighbourhood average income was determined by matching census data to the current area of residence for the patient. The neighbourhood average income for each province was split into quintiles with quintile 1 representing the lowest income and quintile 5 the highest income. The GAD-7 was used to assess generalized anxiety disorder, PHQ-9 was used to assess depression, and CAGE-AID was used to assess problems with drugs or alcohol. Reason for cannabis use was categorized based on keywords around the cannabis indication in the physician's notes (Supplemental Table 1). Patients reporting multiple reasons for seeking medical cannabis were coded into multiple categories. Patients whose records did not identify their reasons for seeking medical cannabis or the reason was very infrequent were coded as having an ‘uncategorized’ reason for seeking medical cannabis.

Patient’s reasons for seeking cannabis were coded into 52 different categories (Supplementary Table 1). 8 of these 52 categories were considered high-level categories into which the other categories were grouped. These high-level categories include pain, mental health, autoimmune conditions, sleep problems, neurological conditions, gastrointestinal conditions, other, and uncategorized.
Evidence Appraisal

The evidence to support cannabis use for each category reason was examined using published reviews and guidelines. A formal search was conducted for all available evidence using PubMed. Timeline was restricted to the most recent 5 years (2015-2020) and the search was restricted to systematic reviews conducted in English, literature reviews and scoping reviews. A separate full systematic or literature review was not needed for this study as we are simply comparing our findings to already pre-existing literature reviews available on cannabis. As seen in Appendix A, we identified a total of 41 systematic and literature reviews. For each category and subcategory, a search was conducted on PubMed for an existing systematic or literature review specific to each category within the past 5 years. Two reviewers determined if there was any evidence and if applicable the level of that evidence. The numbering system to determine level of evidence was directly referenced from the recommendation standards by the National Academies of Science Engineering and Medicine for medical cannabis. We assigned a number from 1 (none or weak evidence), 2 (limited or moderate evidence), or 3 (substantive or conclusive evidence). If there were no existing reviews, we left that specific category without an accompanying reference, and thus, we deemed the category to have none or weak evidence (giving it a “1”). Concurrently, if there were differing levels of evidence, we assigned the level of evidence that was found in the most recent systematic review for that category/subcategory. The findings from each review were also cross-referenced with two expert bodies that have provided guidelines and/or most current evidence available for medical cannabis: 1) National Academies of Science, Engineering and Medicine (NASEM)\(^{30}\); and 2) Canadian evidence for family practice recently compiled by Allan et al\(^{28}\).

Results

Between April 2014 and January 2019, 65,245 adult patients were authorized for medical cannabis use following clinic-based medical assessments. Of these patients, 61,835 (94.8%) were from ON and 3,410 (5.2%) were from AB. Across both Provinces, the mean age of the patients was 52.8 ± 15.4 years and 53.9% of patients were female. The patients resided in neighborhoods distributed across all income quintiles - with the highest income quintile having the lowest proportion of patients (13.9%) (Table 1). The demographics of patients in ON and AB were very similar with respect to age (52.9 ± 15.4 vs. 51.8 ± 15.7 years) and sex (53.8% vs. 55.7% female) in ON and AB, respectively (Table 1). Both provinces also had similar distributions of self-reported questionnaire scores in the GAD-7, PHQ-9, and CAGE-AID assessments - with the majority of patients in both provinces self-reporting no or only mild issues with respect to anxiety (54.5%), depression (49.7%), or addiction (89.1%) (Table 1). Conversely, severe issues were reported by 25.7% of patients for anxiety and 12.5% for depression, and 110.9% reported problems with drugs and alcohol addiction.
| Characteristic | All Patients | Ontario Patients | Alberta Patients |
|---------------|-------------|-----------------|-----------------|
|               | (N = 65245) | (N = 61835)     | (N = 3410)      |
| Age (years)   |             |                 |                 |
| < 21          | 576 (0.9)   | 531 (0.9)       | 45 (1.3)        |
| 21–30         | 4732 (7.3)  | 4451 (7.2)      | 281 (8.2)       |
| 31–40         | 9814 (15.0) | 9269 (15.0)     | 545 (16.0)      |
| 41–50         | 11492 (17.6)| 10904 (17.6)    | 588 (17.2)      |
| 51–60         | 15653 (24.0)| 14873 (24.1)    | 780 (22.9)      |
| 61–70         | 12599 (19.3)| 11948 (19.3)    | 651 (19.1)      |
| 71–80         | 7012 (10.8) | 6656 (10.8)     | 356 (10.4)      |
| 81–90         | 2960 (4.5)  | 2806 (4.5)      | 154 (4.5)       |
| > 90          | 406 (0.6)   | 396 (0.6)       | 10 (0.3)        |
| Sex           |             |                 |                 |
| Female        | 35135 (53.9)| 33236 (53.8)    | 1899 (55.7)     |
| Male          | 30109 (46.1)| 28598 (46.2)    | 1511 (44.3)     |
| Other         | 1 (0.0)     | 1 (0.0)         | -               |
| Neighbourhood Income Quintile | | | |
| 1             | 12814 (19.6)| 11880 (19.2)   | 934 (27.4)      |
| 2             | 14565 (22.3)| 13628 (22.0)   | 937 (27.5)      |
| 3             | 13420 (20.6)| 12894 (20.9)   | 526 (15.4)      |
| 4             | 15068 (23.1)| 14470 (23.4)   | 598 (17.5)      |
| 5             | 9063 (13.9) | 8672 (14.0)    | 391 (11.5)      |
| Missing       | 315 (0.5)   | 291 (0.5)       | 24 (0.7)        |
| GAD-7         | N = 37303   | N = 36962       | N = 341         |
| None          | 11809 (31.7)| 11701 (31.7)   | 108 (31.67)     |
| Mild          | 8496 (22.8) | 8419 (22.8)    | 77 (22.6)       |
| Moderate      | 7400 (19.8) | 7319 (19.8)    | 81 (23.8)       |
| Characteristic     | All Patients | Ontario Patients | Alberta Patients |
|-------------------|--------------|------------------|------------------|
| Severe            | 9598 (25.7)  | 9523 (25.8)      | 75 (22.0)        |
| PHQ-9             | N = 37338    | N = 36995        | N = 343          |
| None              | 8777 (23.5)  | 8689 (23.5)      | 88 (25.7)        |
| Mild              | 9769 (26.2)  | 9686 (26.2)      | 83 (24.2)        |
| Moderate          | 8005 (21.4)  | 7912 (21.4)      | 93 (27.1)        |
| Moderately Severe | 6106 (16.4)  | 6057 (16.4)      | 49 (14.3)        |
| Severe            | 4681 (12.5)  | 4651 (12.6)      | 30 (8.8)         |
| CAGE              | N = 34534    | N = 34316        | N = 218          |
| Negative          | 30758 (89.1) | 30565 (89.1)     | 193 (88.5)       |
| Positive          | 3776 (10.9)  | 3751 (10.9)      | 25 (11.5)        |
| **Method of Use** |              |                  |                  |
| Smoking           | 33024 (50.6) | 31301 (50.6)     | 1723 (50.5)      |
| Vaping            | 30044 (46.1) | 29536 (47.8)     | 508 (14.9)       |
| Ingesting         | 42366 (64.9) | 40448 (65.4)     | 1918 (56.3)      |
| Topical Use       | 2026 (3.1)   | 1980 (3.2)       | 46 (1.4)         |
| Unknown           | 22249 (34.1) | 20757 (33.6)     | 1492 (43.8)      |

Overall, 45,660 (70%) of the patients were categorized into more than one high-level condition (pain, mental health, autoimmune, cancer, sleep problems, neurological, gastrointestinal, other, or uncategorized). 19,585 patients (30.0%) were in one category, 20,843 (32.0%) in two categories, 15,434 (23.7%) in three categories, and 9,383 (14.4%) in four to eight categories. Both ON and AB patient demographics reflected the same top reasons for cannabis authorization: 1) pain (AB = 77%, ON = 76%), 2) mental health (AB = 32.9%, ON = 38.7%), and 3) sleep problems (AB = 28%, ON = 25%) (Table 2). Within the pain category the primary complaints were due to chronic pain conditions resulting in musculoskeletal pain (25% of all patients, 33% of pain patients), arthritic pain (22.7% of all patients, 29.3% of pain patients), and neurologic pain (18.0% of all patients, 23.7% of pain patients). Patients seeking medical cannabis for mental health were mainly concerned with anxiety (24.7% of all patients, 64.1% of mental health patients) and depression (15.7% of all patients, 40.8% of mental health patients). Patients’ sleep problems were primarily insomnia (10.3% of all patients, 42.6% of sleep problem patients). Multiple sclerosis was another condition that was commonly cited (18.5% of all patients) as a reason for obtaining cannabis authorization; however, it is unclear if the underlying reason may have been related to pain or spasticity concerns or both.
| Disorder          | All (N = 65245) | Ontario (N = 61835) | Alberta (N = 3410) |
|-------------------|-----------------|---------------------|--------------------|
| Pain              | 49621 (76.0)    | 46987 (76.0)        | 2634 (77.2)        |
| Endometriosis     | 444 (0.7)       | 416 (0.7)           | 28 (0.8)           |
| Cancer Pain       | 4933 (7.6)      | 4744 (7.7)          | 189 (5.5)          |
| Arthritic Pain    | 14547 (22.7)    | 13730 (22.2)        | 817 (24.0)         |
| Neurologic Pain   | 11772 (18.0)    | 11173 (18.1)        | 599 (17.6)         |
| Musculoskeletal Pain | 16451 (25.2) | 15607 (25.2)        | 1832 (53.7)        |
| Mental Health     | 25081 (38.4)    | 23960 (38.7)        | 1121 (32.9)        |
| Anxiety           | 16088 (24.7)    | 15272 (24.7)        | 816 (23.9)         |
| Depression        | 10236 (15.7)    | 9727 (15.7)         | 509 (14.9)         |
| PTSD              | 2581 (4.0)      | 2463 (4.0)          | 118 (3.5)          |
| Bipolar           | 1340 (2.0)      | 1300 (2.1)          | 40 (1.2)           |
| ADHD              | 984 (1.5)       | 935 (1.5)           | 49 (1.4)           |
| Panic Disorder    | 2331 (3.6)      | 2272 (3.7)          | 59 (1.7)           |
| ADD               | 4854 (7.4)      | 4774 (7.7)          | 80 (2.4)           |
| Mood Disorder     | 2542 (3.9)      | 2457 (4.0)          | 85 (2.5)           |
| Stress            | 2370 (3.6)      | 2285 (3.7)          | 85 (2.5)           |
| OCD               | 424 (0.6)       | 398 (0.6)           | 26 (0.8)           |
| Schizophrenia     | 325 (0.5)       | 319 (0.5)           | 6 (0.2)            |
| Autoimmune        | 13729 (21.0)    | 13243 (21.4)        | 486 (14.2)         |
| Multiple Sclerosis| 12084 (18.5)    | 11666 (18.9)        | 418 (12.3)         |
| IBS               | 1741 (2.7)      | 1686 (2.7)          | 55 (1.6)           |
| Lupus             | 301 (0.5)       | 285 (0.5)           | 16 (0.5)           |
| Sjogren's         | 97 (0.1)        | 90 (0.2)            | 7 (0.2)            |
| Sleep problems    | 16122 (24.7)    | 15159 (24.5)        | 963 (28.2)         |
| Insomnia          | 6706 (10.3)     | 6003 (9.7)          | 703 (20.6)         |

PTSD: Post-traumatic stress disorder  
ADHD: Attention deficit hyperactivity disorder  
ADD: Attention deficit disorder  
OCD: Obsessive compulsive disorder  
IBS: Irritable bowel syndrome  
ALS: Amyotrophic lateral sclerosis  
COPD: Chronic obstructive pulmonary disease
| Disorder                      | All (N = 65245) | Ontario (N = 61835) | Alberta (N = 3410) |
|-------------------------------|----------------|---------------------|-------------------|
| Fatigue                       | 1835 (2.8)     | 1787 (2.9)          | 48 (1.4)          |
| Sleep Apnea                   | 904 (1.4)      | 879 (1.4)           | 25 (0.7)          |
| Neurological                  | 5052 (7.7)     | 4829 (7.8)          | 223 (6.5)         |
| Neuropathy                    | 2079 (3.2)     | 1992 (3.2)          | 87 (2.6)          |
| Parkinson's                   | 678 (1.0)      | 642 (1.0)           | 36 (1.1)          |
| Seizure                       | 1150 (1.8)     | 1111 (1.8)          | 39 (1.1)          |
| Epilepsy                      | 606 (0.9)      | 576 (0.9)           | 30 (0.9)          |
| Restless Leg Syndrome         | 406 (0.6)      | 384 (0.6)           | 22 (0.7)          |
| Tremor                        | 894 (1.4)      | 850 (1.4)           | 44 (1.3)          |
| ALS                           | 108 (0.2)      | 107 (0.2)           | 1 (0.03)          |
| Cerebral Palsy                | 107 (0.2)      | 106 (0.2)           | 1 (0.03)          |
| Gastrointestinal              | 2818 (4.3)     | 2710 (4.4)          | 108 (3.2)         |
| Crohn's                       | 764 (1.2)      | 731 (1.2)           | 33 (1.0)          |
| Colitis                       | 469 (0.7)      | 444 (0.7)           | 25 (0.7)          |
| Other                         | 10517 (16.1)   | 10081 (16.3)        | 436 (12.8)        |
| Osteoporosis                  | 3274 (5.0)     | 3110 (5.0)          | 164 (4.8)         |
| Nausea                        | 2938 (4.5)     | 2855 (4.6)          | 83 (2.4)          |
| Cancer Related Nausea         | 1049 (1.6)     | 1025 (1.7)          | 24 (0.7)          |
| Diabetes                      | 1348 (2.1)     | 1251 (2.0)          | 97 (2.8)          |
| Appetite                      | 2307 (3.5)     | 2250 (3.6)          | 57 (1.7)          |
| Cancer Related Appetite       | 975 (1.5)      | 954 (1.5)           | 21 (0.6)          |
| COPD                          | 936 (1.4)      | 907 (1.5)           | 29 (0.8)          |
| Concussion                    | 524 (0.8)      | 501 (0.8)           | 23 (0.7)          |
| Autism                        | 198 (0.3)      | 188 (0.3)           | 10 (0.3)          |
| Glaucoma                      | 295 (0.4)      | 287 (0.5)           | 8 (0.2)           |
| Huntington's                  | 17 (0.03)      | 16 (0.03)           | 1 (0.03)          |

**PTSD**: Post-traumatic stress disorder  **ADHD**: Attention deficit hyperactivity disorder  **ADD**: Attention deficit disorder  **OCD**: Obsessive compulsive disorder  **IBS**: Irritable bowel syndrome  **ALS**: Amyotrophic lateral sclerosis  **COPD**: Chronic obstructive pulmonary disease
Of the conditions reported, those with substantive or conclusive evidence to support use include refractory pain related to cancer (7.6% of patients), chronic neuropathic pain (18.0% of patients), refractory spasticity conditions (7.7% of patients), short-term sleep improvement (24.7% of patients), and cancer-related nausea (1.6% of patients)\(^5,23,30\). While there is evidence to support the use for these conditions, it was noted as being weak to moderate evidence in the guidelines, so cannabis is not recommended as a first-line form of therapy. Glaucoma (0.4% of patients) was the only condition examined that had limited evidence and reviews or guidelines suggested that cannabis should be recommended against\(^30\). There was no specific evidence to support or refute the use of medical cannabis for Attention Deficit Disorder, Obsessive Compulsive Disorder, Lupus, Sjogren’s, or Osteoporosis. The remaining conditions examined (8.9%) had either limited or insufficient evidence available so recommendations could not be made.

In all, roughly 16483 (25.3%) patients are seeking medical cannabis for reasons with limited or insufficient evidence to support the therapeutic benefits of medical cannabis for their condition based on currently available evidence (Appendix A). This includes some of the conditions most frequently cited as reasons for prescription such as non-neuropathic musculoskeletal pain (25.2% of patients), arthritic pain (22.7% of patients), anxiety (24.7% of patients), and depression (15.7% of patients). The majority of the remaining conditions, as mentioned, have either no available evidence or show weak evidence in showing an association with its use for that particular condition.

### Discussion

This population-based cohort study showed important characteristics about adult patients who were medically authorized for cannabis in ON and AB, Canada. Overall, the demographics of the adult population in ON and AB were comparable for both mean age and sex at the index date of authorization. Patients’ average age was over 50 years and overall sex distribution was similar. The primary reasons for cannabis authorization were similar between ON and AB with pain, mental health, and sleep problems as the most common.

However, 70% of patients in ON and AB were categorized into more than one high-level condition (pain, mental health, autoimmune, cancer, sleep problems, neurological, gastrointestinal, other, or uncategorized) for cannabis authorization suggesting these patients have multiple comorbidities which are not currently being adequately addressed with more traditional medical therapies. This also may suggest that the nature of therapeutic applications of cannabis are multi-faceted. For example, a patient

| Disorder                      | All (N = 65245) | Ontario (N = 61835) | Alberta (N = 3410) |
|-------------------------------|-----------------|---------------------|--------------------|
| Uncategorized                 | 5796 (8.9)      | 5729 (9.3)          | 67 (2.0)           |

\(PTSD\): Post-traumatic stress disorder \(ADHD\): Attention deficit hyperactivity disorder \(ADD\): Attention deficit disorder \(OCD\): Obsessive compulsive disorder \(IBS\): Irritable bowel syndrome \(ALS\): Amyotrophic lateral sclerosis \(COPD\): Chronic obstructive pulmonary disease
experiencing cancer pain may also suffer from sleep problems. Hence, the multi-symptom\textsuperscript{16} nature of patients who seek cannabis may make identification of the efficacy of medical cannabis, per symptom, difficult. From a quality of life standpoint, medical cannabis may be viewed as effective for one symptom (ex: sleep) - however if improvement of pain or cancer were also included as outcomes - then cannabis may appear ineffective. These outcomes may be a contributing factor to the mixed results\textsuperscript{2} on cannabis efficacy on treatment in the literature.

Overall, the majority of reasons for cannabis authorization were found to have limited or insufficient evidence to support the use of medical cannabis for those reasons, as aligned with the literature found on these conditions. That is not to suggest patients may not be experience benefit from medical cannabis but that the scientific evidence to support the indication has not been established or in many cases research has not been conducted at all. Previous research studies have reported a level of substantive evidence for medical cannabis’ use in the alleviation of pain(5, 27, 29). Both Canadian clinicians(5) and the National Academies of Science, Engineering and Medicine(30) have concurred that medical cannabis use may be effective in the management of chronic pain. In addition, they also suggest medical cannabis may be effective for chemotherapy-induced vomiting/nausea, and multiple sclerosis spasticity symptoms.(5, 30) Further, previous research has shown that there is an inherent psychological\textsuperscript{31} element to medical cannabis use, in particular for relieving anxiety(4, 14) and depression(18, 19). A significant portion of mental health outcome studies on medical cannabis also included its frequent utilization for both sleep problems(21, 22) and post-traumatic stress disorder(13, 15).

Otherwise, clinician recommendations emphasize limiting medical cannabis use for any other ailment (as a first-choice treatment plan)(5, 23). Our study shows that AB and ON physicians are prescribing medical cannabis for over 50 listed conditions (Supplementary Table 1). At least 25% of patients in this study were using medical cannabis for reasons not currently supported by evidence. Moreover, 25% is likely a very conservative estimate as it assumed that all reported reasons met the specific criteria which has the support of evidence (i.e. all cancer pain was refractory cancer pain, all patients stating diabetes and pain had neuropathic diabetic pain, all sleep problems were short-term etc.). This observation aligns with the systematic review by Lim et al.\textsuperscript{12} - that shows that a significant portion of medical cannabis is used for a diverse range of specific health conditions or disorders. Furthermore, the systematic review showed little to no evidence supporting medical cannabis use on the treatment of these other health conditions. Likewise, NASEM(23) has also reported that there is limited to insufficient evidence for medical cannabis use on any health conditions other than chronic pain. This is also supported by Canadian evidence(5) on limiting cannabis use as a first- or second-line of treatment. The guidelines, however, do make an exception for a small consideration of neuropathic pain – but this is emphasized as a weak recommendation.

The major strength of this study is that it is currently Canada’s largest study on medical cannabis authorized adult patients. Therefore, the data from this study provides current and critical information about Canadian patients seeking cannabis as a form of therapy for various health reasons. The findings from this study contribute to the knowledge base on population-level use beyond its nonmedical uses.
Our analyses further provide evidence on important subgroups of patients who are currently using medical cannabis for treatment of over 200 conditions.

The limitations of this study are that our data are restricted to only patients who have attended a cannabis medical clinic. It is also possible that responders to the questionnaires provide information overstating their health symptoms as a means to increase their likelihood of being authorized medical cannabis. We also did not appraise the level of evidence ourselves and used the appraisals from other studies (Appendix A). The Canadian evidence and the NASEM guidelines often had differing opinions on the strength of evidence with the US guidelines saying substantive evidence and the Canadian evidence reporting weak evidence. When differences were found, the recommendations from the Canadian evidence recommendations were used. Finally, we have no method to determine if cannabis was being considered as a first, second or alterative line of therapy – in most cases it is more than plausible it was not used as first line.

**Conclusions**

Overall, medical cannabis continues to be authorized for numerous other conditions that do not have any evidential basis supporting its utilization. Thus, ongoing epidemiological and randomized controlled trials on medical cannabis use on these health conditions is warranted to identify its safety and health benefits at the population-level.

We believe our findings contribute critical information to frontline clinicians, health care administration, and federal/provincial governments to capture clarity on the current population of medical cannabis users, reasons for authorization, and the paucity of evidence to help guide evidence-based decisions. A key future direction for this cohort, and others, will be to evaluate the impacts and safety of medical cannabis over both the short- and long-term for the vast array of conditions noted. Notably, this study is not meant to correlate high frequency of authorization as recommendation for its usage. Adults seeking medical cannabis should continue to approach this medication with caution and consider all available evidence regarding its usage. Clinicians providing medical cannabis authorization should be advised to follow recommended clinical guidelines and ensure to continue to provide best-practice standards of care.

**Abbreviations**

AB – Alberta

CAGE-AID - CAGE Questionnaire Adapted to Include Drugs

NASEM – National Academies of Science, Engineering and Medicine

ON- Ontario
GAD-7 - Generalized Anxiety Disorder 7-item
PHQ-9 - Patient Health Questionnaire

Declarations

Ethics Approval

The study was approved by the University of Alberta Health Research Ethics Board (PRO 00068887) and the Veritas Research Ethics Board in Ontario (16111-13:21:103-01-2017).

Consent to Participate

Patients and the public were not involved in designing, conducting, or reporting this research project as it was not directly applicable to this project.

Consent for publication

Not applicable

Availability of data and materials

The dissemination of data results to study participants and or patient organizations in this research project is not possible/applicable. This study is based in part on data provided by Canadian Cannabis Clinics and CanvasRx Inc. The interpretation and conclusions contained herein are those of the researchers and do not necessarily represent the views of Canadian Cannabis Clinics or Canvas Rx Inc., each of whom do not express any opinion in relation to this study.

Competing Interests

JRBD is a former board member of Aurora Cannabis Inc., which is a for-profit, company licensed for the cultivation and sale of medical cannabis. In the past, JGH has worked as a paid advisor and speaker for Canadian Cannabis Clinics (he no longer has ties with the cannabis clinics). JRBD has a financial interest in Aurora Cannabis Inc. DTE holds a Mitacs Grant with Aurora as a partner. Mitacs is a national, not-for-profit organization that works with universities, private companies, and both federal and provincial governments, to build partnerships and administer research that supports industrial and social innovation in Canada. DTE does not have any past or present financial interest in the companies involved. CL, JMR, EH, SK have no conflicts of interest to declare. Moreover, the research funders and companies listed were not involved in any aspect of the design or write-up of the study and all analysis was performed independent from the funders and companies.

Funding
This study was funded by a Canadian Institutes of Health research Project grant (CIHR PS 159668) to DTE, JGH, EH, and JRBD.

**Authors’ Contribution**

DTE, JRBD, JGH, EH designed the study and DTE and JRBD acquired the data. DTE and JMR analyzed the data. CL, JMR, and DTE drafted the manuscript. All other authors (including SK) revised it critically for important intellectual content and approved the final version to be published. All authors are accountable for the work and integrity of the work.

**Acknowledgements**

The corresponding author and guarantor accepts full responsibility of the work and/or conduct of the study, had access to the data and controlled the decision to publish. DTE attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

DTE affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and if relevant) have been explained.

**References**

1. Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis - the Canadian perspective. J Pain Res. 2016;9:735–44.
2. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–73.
3. Makary P, Parmar JR, Mims N, Khanfar NM, Freeman RA. Patient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain. J Pain Palliat Care Pharmacother. 2018;32(4):216–25.
4. Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety. 2017;34(11):1006–17.
5. Allan GM, Ramji J, Perry D, Ton J, Beahm NP, Crisp N, et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician. 2018;64(2):111–20.
6. Lake S, Kerr T, Montaner J. Prescribing medical cannabis in Canada: Are we being too cautious? Can J Public Health. 2015;106(5):e328-30.
7. Tafelski S, Hauser W, Schafer M. Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews. Schmerz. 2016;30(1):14–24.
8. Wall MM, Liu J, Hasin DS, Blanco C, Olfson M. Use of marijuana exclusively for medical purposes. Drug Alcohol Depend. 2019;195:13–5.
9. Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, et al. A selective review of medical cannabis in cancer pain management. Ann Palliat Med. 2017;6(Suppl 2):215-S22.

10. Maharajan MK, Yong YJ, Yip HY, Woon SS, Yeap KM, Yap KY, et al. Medical cannabis for chronic pain: can it make a difference in pain management? J Anesth. 2019.

11. Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3(7):e341-e50.

12. Lim K, See YM, Lee J. A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. Clin Psychopharmacol Neurosci. 2017;15(4):301–12.

13. Steenkamp MM, Blessing EM, Galatzer-Levy IR, Hollahan LC, Anderson WT. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. Depress Anxiety. 2017;34(3):207–16.

14. Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020;20(1):24.

15. Orsolini L, Chiappini S, Volpe U, Berardis D, Latini R, Papanti GD, et al. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Medicina (Kaunas). 2019;55(9).

16. Turna J, Simpson W, Patterson B, Lucas P, Van Ameringen M. Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. J Psychiatr Res. 2019;111:134–9.

17. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041.

18. Feingold D, Brill S, Goor-Aryeh I, Delayahu Y, Lev-Ran S. The association between severity of depression and prescription opioid misuse among chronic pain patients with and without anxiety: A cross-sectional study. J Affect Disord. 2018;235:293–302.

19. Taub S, Feingold D, Rehm J, Lev-Ran S. Patterns of cannabis use and clinical correlates among individuals with Major Depressive Disorder and Bipolar Disorder. Compr Psychiatry. 2018;80:89–96.

20. Katz D, Katz I, Porat-Katz BS, Shoenfeld Y. Medical cannabis: Another piece in the mosaic of autoimmunity? Clin Pharmacol Ther. 2017;101(2):230–8.

21. Sznitman SR, Vulfsons S, Meiri D, Weinstein G. Medical cannabis and insomnia in older adults with chronic pain: a cross-sectional study. BMJ Support Palliat Care. 2020.

22. Choi S, Huang BC, Gamaldo CE. Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions. J Clin Neurophysiol. 2020;37(1):39–49.

23. Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018;49:7–11.

24. Andrews CN, Devlin SM, Le Foll B, Fischer B, Tse F, Storr M, et al. Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders.
25. Agarwal R, Burke SL, Maddux M. Current state of evidence of cannabis utilization for treatment of autism spectrum disorders. BMC Psychiatry. 2019;19(1):328.

26. Abdallah SJ, Smith BM, Ware MA, Moore M, Li PZ, Bourbeau J, et al. Effect of Vaporized Cannabis on Exertional Breathlessness and Exercise Endurance in Advanced Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. Ann Am Thorac Soc. 2018;15(10):1146–58.

27. O'Connell M, Sandgren M, Frantzen L, Bower E, Erickson B. Medical Cannabis: Effects on Opioid and Benzodiazepine Requirements for Pain Control. Ann Pharmacother. 2019;53(11):1081–6.

28. Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, et al. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64(2):e78–94.

29. Romero-Sandoval EA, Fincham JE, Kolano AL, Sharpe BN, Alvarado-Vazquez PA. Cannabis for Chronic Pain: Challenges and Considerations. Pharmacotherapy. 2018;38(6):651–62.

30. The Health Effects of Cannabis and Cannabinoids. The Current State of Evidence and Recommendations for Research. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC)2017.

31. Botsford SL, Yang S, George TP. Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential. Am J Addict. 2020;29(1):9–26.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryTables.docx